Pfizer-BioNTech will stop adding patients to its Paxlovid phase 2/3 trial after failing to prove the antiviral treatment reduced the relative risk of contracting COVID-19.
Read the full post on Becker's Hospital Review - Healthcare News
Pfizer halts Paxlovid trial for standard-risk patients
